immuno-oncology

News

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial

AstraZeneca’s cancer immunotherapy Imfinzi broke new ground when it was approved in 2018 for locally advanced non-small cell lung cancer (NSCLC) that can’t be treated with

News

BioNTech flashes the cash, adding tumour drug in $1bn deal

Fresh from slashing its predictions for COVID-19 vaccine sales this year, mRNA specialist BioNTech has used some of its extensive cash reserves to bolster its pipeline in

News

Imfinzi faces Keytruda competition in biliary tract cancer

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch

News

GSK claims a first with Jemperli in endometrial cancer

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.

News

Keytruda gets surgery-spanning OK from FDA in early NSCLC

MSD’s Keytruda has become the first immunotherapy in the US that can be used continuously, before and after surgery, in patients with early-stage non-small cell lung cance

News

Exscientia trims pipeline to focus on top cancer prospects

UK biotech Exscientia has tapped the brakes on the rapid expansion of its R&D pipeline, narrowing its in-house activities to oncology programmes that it says offer the

AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial

BioNTech flashes the cash, adding tumour drug in $1bn deal

Imfinzi faces Keytruda competition in biliary tract cancer

GSK claims a first with Jemperli in endometrial cancer

Keytruda gets surgery-spanning OK from FDA in early NSCLC

Exscientia trims pipeline to focus on top cancer prospects

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

immuno-oncology

Editor's Picks